Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers

21 Jun 2016

Abstract excerpt

The azanucleosides azacitidine and decitabine are currently used for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in patients not only eligible for intensive chemotherapy but are also being explored in other hematologic and solid cancers. Based on their capacity to interfere with the DNA methylation machinery, these drugs are also referred to as hypomethylating agents (HMAs)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Retinoids in leukemia and cellular processes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27330573
DOI: 10.1186/s13148-016-0237-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersPMID 27330573Read ↗

Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating AgentsSemantic proximity Read ↗

Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinicSemantic proximity Read ↗

The use of hypomethylating agents in the treatment of hematologic malignanciesSemantic proximity Read ↗

Clinical development of demethylating agents in hematologySemantic proximity Read ↗

DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AMLSemantic proximity Read ↗

Demethylating Agents in the Treatment of CancerSemantic proximity Read ↗

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic ToolSemantic proximity Read ↗

DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studiesSemantic proximity Read ↗

DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences.Semantic proximity Read ↗

DNA Methylation–Targeted DrugsSemantic proximity Read ↗

Clinical Results of Hypomethylating Agents in AML TreatmentSemantic proximity Read ↗

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the EpicenterSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.